Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06176963
Other study ID # SB11-2001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 21, 2023
Est. completion date December 12, 2023

Study information

Verified date December 2023
Source Samsung Bioepis Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar). Healthcare Professionals (HCPs) followed the Instructions for Use (IFU) to prepare and administer SB11 PFS with intravitreal injection to subjects with nAMD or Macular Oedema Secondary to RVO.


Description:

This is an open-label, single group, single dose study in subjects with nAMD or Macular Oedema Secondary to RVO. Screening and Day 1 can be performed on the same day. Subjects will receive ITV injection of SB11 PFS (0.5 mg ranibizumab in 0.05 mL) on Day 1, and follow up visit will be made on Day 1 (+2).


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date December 12, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Neovascular AMD or macular oedema secondary to RVO in the study eye - Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the ophthalmologist (e.g., retina specialist) - Aged 18 years and older at the time of signing the informed consent form (ICF) - Written ICF must be obtained from the subject prior to any study-related procedure (if the subject cannot read ICF, an impartial witness will be present during the entire informed consent discussion) - Willingness and ability to undertake all scheduled visits and assessments Exclusion Criteria: - Best Corrected Visual Acuity (BCVA) of the level of Finger Count or worse [i.e., 0 letter reading using Early Treatment Diabetic Retinopathy Study (ETDRS) chart] in one or both eyes at Screening or at Day 1 - History of and/or current intraocular inflammation (any grading from trace and greater is excluded), including non-infectious uveitis, infectious uveitis, or scleritis, or history of sterile inflammatory reaction after the past ITV injections with any agent in either eye - Active or suspected infectious disease, or active disorder that preclude safe use of IP at the discretion of the Investigator, in either eye or adnexa of either eye at Screening or at Day 1 - History of excessive bleeding and recurrent haemorrhages, including any prior excessive intraocular bleeding or haemorrhages after ITV injection or intraocular procedures in either eye - History of massive subconjunctival haemorrhages of concern reported by the subject after an ITV injection in either eye - Uncontrolled intraocular pressure (IOP) greater than (=) 25 mmHg in the study eye at Screening or at Day 1 - Treatment with any ITV injection within the 30 days prior to Day 1 in the study eye - Any invasive ocular surgery including retinal detachment surgery, long-acting ocular therapeutic agent/implant including corticosteroid, or ocular drug release device implant (approved or investigational) in the study eye within 90 days prior to Day 1 or planned intraocular surgery within next 28 days after Day 1 - Ocular laser surgery in study eye at any time within the past 30 days prior to Day 1 - Treatment with any ocular IP in either eye within 90 days prior to Day 1 - Treatment with systemic anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days prior to Day 1 - Receipt of any systemic (non-ocular) IP within 180 days prior to Day 1 - Use of therapies that are known to be toxic to ocular tissue within the 180 days prior to Day 1, including, but not limited to, deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines, vigabatrin, or ethambutol - Known ocular or non-ocular conditions that per the ophthalmologist (e.g., retina specialist) represent a contraindication to ranibizumab use in the patient or may represent an unwarranted patient risk - Uncontrolled hypertension (defined as systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg while sitting confirmed after repeated measurement) at Screening or Day 1 - Current systemic infectious disease or therapy for active infectious disease - Pregnant or lactating women at Screening or at Day 1 Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
SB11 PFS
SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection

Locations

Country Name City State
Poland SB Investigational Site Katowice
Poland SB Investigational Site Kraków
Poland SB Investigational Site Olsztyn

Sponsors (1)

Lead Sponsor Collaborator
Samsung Bioepis Co., Ltd.

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of successful task completions Total of 12 tasks were evaluated, and the percentage of HCP's successful task completions were measured. Day 1
Secondary Percentage of successful completion on critical tasks Total of 6 tasks were considered as critical task, and the percentage of HCP's successful completion on critical tasks were evaluated. Day 1
Secondary Percentage of successful completion on essential tasks Total of 6 tasks were considered as essential task, and the percentage of HCP's successful completion on essential tasks were evaluated. Day 1
See also
  Status Clinical Trial Phase
Completed NCT04292912 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema Phase 1
Recruiting NCT05976139 - Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies N/A
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT01660802 - Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO) Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04592419 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Completed NCT02623673 - Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema N/A
Terminated NCT01946399 - Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF N/A
Completed NCT01428388 - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion N/A
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Recruiting NCT01023113 - To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation N/A
Completed NCT00970957 - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Phase 3
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Terminated NCT00918554 - Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Phase 4
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00411970 - 20- Versus 23- Gauge System for Pars Plana Vitrectomy Phase 4
Completed NCT00668239 - Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser N/A
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4